← All trials
NCT04665895
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 10, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Jun 30, 2022
- First posted
- Dec 14, 2020
- Last posted
- Dec 14, 2020
- Enrollment
- 451
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Respirent Pharmaceuticals Co Ltd.Lead sponsor
- University of IoanninaOverall official - principal investigator
- BECRO Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.